Jackson Creek Investment Advisors LLC Cuts Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Jackson Creek Investment Advisors LLC cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.9% in the 4th quarter, HoldingsChannel reports. The fund owned 4,674 shares of the company’s stock after selling 92 shares during the quarter. Medpace accounts for 0.5% of Jackson Creek Investment Advisors LLC’s portfolio, making the stock its 16th biggest position. Jackson Creek Investment Advisors LLC’s holdings in Medpace were worth $1,433,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Medpace by 2.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after acquiring an additional 148 shares during the last quarter. Portside Wealth Group LLC grew its stake in shares of Medpace by 14.8% in the fourth quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after purchasing an additional 183 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock valued at $1,090,000 after purchasing an additional 2,774 shares during the period. Louisiana State Employees Retirement System bought a new position in Medpace during the 4th quarter valued at approximately $1,992,000. Finally, Chase Investment Counsel Corp grew its position in shares of Medpace by 3.2% in the 3rd quarter. Chase Investment Counsel Corp now owns 9,849 shares of the company’s stock worth $2,384,000 after buying an additional 301 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 3.0 %

NASDAQ MEDP traded down $11.86 during trading on Tuesday, hitting $388.35. 224,805 shares of the stock traded hands, compared to its average volume of 250,405. The company has a market capitalization of $12.03 billion, a P/E ratio of 40.57, a price-to-earnings-growth ratio of 1.97 and a beta of 1.38. Medpace Holdings, Inc. has a 12-month low of $197.39 and a 12-month high of $421.00. The firm has a 50-day simple moving average of $398.00 and a 200-day simple moving average of $327.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter in the previous year, the business posted $2.27 earnings per share. Medpace’s quarterly revenue was up 17.7% on a year-over-year basis. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ashley M. Keating sold 250 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total value of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at $102,467.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Ashley M. Keating sold 250 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total value of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at $102,467.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 189,340 shares of company stock worth $76,651,647. Insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of several research analyst reports. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and boosted their price target for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price target on the stock. Guggenheim increased their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Finally, Robert W. Baird raised their target price on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $443.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.